Positron Emission Tomography (PET) Scanning in Dopamine Disorders: Parkinson's Disease and Schizophrenia
概览
- 阶段
- 不适用
- 干预措施
- 18F-Fluoro-L-dopa
- 疾病 / 适应症
- Schizophrenia
- 发起方
- National Institute of Mental Health (NIMH)
- 入组人数
- 502
- 试验地点
- 1
- 主要终点
- To explore with positron emission tomography (PET) the pathophysiology and cerebral consequences of dopaminergic dysregulation.
- 状态
- 已完成
- 最后更新
- 3天前
概览
简要总结
This is an in vivo positron emission tomography (PET) study of regional cerebral dopamine and blood flow in normal volunteers, persons with Parkinson s disease (both familial and sporadic), and those with schizophrenia spectrum disorders. The latter also sign consent for NIH approved protocol 89-M-0160, "Inpatient Evaluation of Neuropsychiatric Patients," PI: Daniel Eisenberg, M.D. Using PET with 6-[F-18] Fluoro-L-dopa (FDOPA) and (15)0-H2O in a single scan session, both presynaptic dopaminergic function and regional cerebral blood flow (rCBF) are assessed. The kinetic rate constant (Ki) for presynaptic dopaminergic uptake in striatum and other regions is calculated. We compare Ki across subject groups and relate the findings to rCBF. Findings are also related to allelic variation in genes of interest, for determination of which participants sign separate consent for NIH approved protocol 95-M-0150 Neurobiological Investigation of Patients with Schizophrenia Spectrum Disorders and Their Siblings, PI: Karen F. Berman, MD. We also draw comparisons between subjects with inherited vs. sporadic Parkinson s disease to determine whether the PET phenotype is the same in both groups, and we compare system-level, circuit-based pathophysiology across PD and schizophrenia groups. Each subject is further screened with an MRI to rule out structural abnormalities and also to further delineate areas of interest in the PET scans....
详细描述
This is an in vivo positron emission tomography (PET) study of regional cerebral dopamine and blood flow in normal volunteers, persons with Parkinson s disease (both familial and sporadic), and those with schizophrenia spectrum disorders. The latter also sign consent for NIH approved protocol 89-M-0160, "Inpatient Evaluation of Neuropsychiatric Patients," PI: Daniel Eisenberg, M.D. Using PET with 6-\[F-18\] Fluoro-L-dopa (FDOPA) and (15)0-H2O in a single scan session, both presynaptic dopaminergic function and regional cerebral blood flow (rCBF) are assessed. The kinetic rate constant (Ki) for presynaptic dopaminergic uptake in striatum and other regions is calculated. We compare Ki across subject groups and relate the findings to rCBF. Findings are also related to allelic variation in genes of interest, for determination of which participants sign separate consent for NIH approved protocol 95-M-0150 Neurobiological Investigation of Patients with Schizophrenia Spectrum Disorders and Their Siblings, PI: Karen F. Berman, MD. We also draw comparisons between subjects with inherited vs. sporadic Parkinson s disease to determine whether the PET phenotype is the same in both groups, and we compare system-level, circuit-based pathophysiology across PD and schizophrenia groups. Each subject is further screened with an MRI to rule out structural abnormalities and also to further delineate areas of interest in the PET scans.
研究者
入排标准
入选标准
- •INCLUSION CRITERIA:
- •Age between 18 and 90 years
- •Ability to give informed consent
- •Ability to read and write
- •Ability to give adequate medical and neuropsychiatric history.
- •PARKINSONS DISEASE:
- •Individuals over the age of 18 from families in which an autosomal dominant form of Parkinson's disease is suspected based on pedigree analysis.
- •Each subject will have a medical history and brief neurological examination.
- •The diagnosis in probands must be supported by accepted clinical criteria: tremor, bradykinesia, and responsiveness to L-DOPA.
- •Equivocally affected individuals will also be included in order to aid in their phenotypic classification as will at risk individuals who show no neurological signs.
排除标准
- •Will include medical illness that would affect cerebral blood flow or dopamine
- •Current pregnancy
- •Current breast feeding
- •Possible exposure to radiation exceeding RSC guidelines
- •History of any (excepting nicotinerelated) DSM5-defined moderate to severe substance use disorder (or DSM-IV-defined substance dependence).
- •Cumulative lifetime history of any (excepting nicotine-related) DSM5-defined mild substance use disorder (or any DSM-IV-defined substance abuse),either in excess of 5 years total or not in remission for at least 6 months,
- •Inability to stay caffeine- and nicotine-free for 4 hours
- •Current suicidality or assaultiveness
- •History of movement disorder
- •History of head injury requiring hospitalization
研究组 & 干预措施
Patients - schizophrenia spectrum disorders
Patients - schizophrenia spectrum disorders
干预措施: 18F-Fluoro-L-dopa
Healthy volunteers
Healthy volunteers.
干预措施: O-15 Water
Patients - Parkinsons
Patients with Parkinsons
干预措施: 18F-Fluoro-L-dopa
Patients - schizophrenia spectrum disorders
Patients - schizophrenia spectrum disorders
干预措施: O-15 Water
Patients - Parkinsons
Patients with Parkinsons
干预措施: O-15 Water
结局指标
主要结局
To explore with positron emission tomography (PET) the pathophysiology and cerebral consequences of dopaminergic dysregulation.
时间窗: Ongoing
To explore with positron emission tomography (PET) the pathophysiology and cerebral consequences of dopaminergic dysregulation.